Pregabalin Capsule
Product Images NDC 71610-998

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-998). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0998 30)

Label for Pregabalin 150 mg capsules, containing 30 capsules. The label shows the product name, strength, NDC number 71610-998-30, and manufacturer details including SciGen Pharmaceuticals Inc and Aphena Pharma Solutions - Tennessee, LLC. It includes storage instructions and a habit-forming warning, specifying that the capsules are for prescription use only.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph depicting percent improvement in pain from baseline on the x-axis against percent of patients improved on the y-axis. Four curves represent different groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo. The graph shows comparative patient improvement across these dosages and placebo.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day with placebo. The vertical axis represents the percent of patients improved, and the horizontal axis shows percent improvement in pain from baseline, ranging from 0 to 100 percent.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph depicting percent of patients improved versus percent improvement in pain from baseline. The graph compares four groups: Pregabalin 300 mg twice daily, Pregabalin 150 mg twice daily, Pregabalin 75 mg twice daily, and placebo, showing relative effectiveness in pain improvement.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph showing percent improvement in pain from baseline plotted against the percent of patients improved. It compares Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo groups. The x-axis represents percent improvement in pain, and the y-axis represents the percent of patients improved.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph depicting the percent of patients improved versus percent improvement in pain from baseline. It compares Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo, showing trends of patient improvement at different pain reduction levels.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar chart depicting responder rates (%) in two clinical studies, labeled Study E1 and Study E3. The x-axis shows different treatment groups including placebo and varying dosages of Pregabalin (50 mg/day to 600 mg/day for Study E1, 300 mg/day and 600 mg/day for Study E3). The y-axis measures responder rates from 0% to 60%. Each treatment group's responder rate is represented by vertical bars with sample sizes noted below. Statistically significant results compared to placebo are marked with an asterisk.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph showing seizure reduction as median percent change from baseline versus dose in mg/day. The graph compares data from four studies (E1 BD, E2 TID, E3 BD, E3 TID) with different dosing schedules, indicating p-values for statistical significance at various dose points.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline. Four lines compare Pregabalin at daily doses of 800mg, 450mg, 300mg, and placebo, depicting the relationship between pain improvement percentages and patient response rates.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival curve chart displaying the estimated percentage of subjects without LTR (loss to response) over 180 days. Two curves are shown: a solid line representing Pregabalin and a dashed line representing Placebo, with the Pregabalin group maintaining a higher percentage of subjects without LTR throughout the period.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing the percent of subjects improved over time from baseline to week 12 for Pregabalin and placebo groups. The x-axis shows the percent improved from baseline to week 12, and the y-axis shows the percent of subjects improved. The graph shows a solid line for Pregabalin and a dashed line for placebo, indicating higher improvement percentages for Pregabalin at various points.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line graph comparing the percentage of subjects improved by various levels from baseline to Week 16 BOCF between Pregabalin and Placebo. The x-axis represents percent improvement, and the y-axis shows the percent of subjects improved. The graph includes two lines: a solid line for Pregabalin and a dashed line for Placebo, illustrating greater improvement percentages for Pregabalin across the spectrum.*

FDA Label Image

Figure 13 (Pregabalin Fig13)

A vertical bar chart displaying responder rates (%) for Pregabalin at doses 2.5 mg/kg/day and 10 mg/kg/day compared to placebo. The responder rates are approximately 22.6% for placebo, 29.1% for 2.5 mg/kg/day, and 40.6% for 10 mg/kg/day. Sample sizes are shown below each bar.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula presentation depicting creatinine clearance (CLcr) calculation, showing the equation involving age in years, body weight in kilograms, serum creatinine in mg/dL, and a factor of 0.85 adjustment for female patients.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of Pregabalin, showing its molecular arrangement, including the amino group and carboxylic acid group, consistent with the generic compound depicted in the product data.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.